-
Product Insights
NewLymphocryptovirus Infections – Drugs In Development, 2024
Empower your strategies with our Lymphocryptovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Lymphocryptovirus infections are caused by a genus of herpesviruses that infect humans and other primates. The most well-known lymphocryptovirus is the Epstein-Barr virus (EBV), which can cause mononucleosis, lymphoma, and nasopharyngeal carcinoma in humans. Lymphocryptovirus infections are usually latent, meaning that the virus remains dormant in the host cells until it is reactivated by stress or immune suppression. Lymphocryptovirus infections can be...
-
Product Insights
NewAcute Lung Injury – Drugs In Development, 2024
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions. Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke,...
-
Product Insights
NewSquamous Non-Small Cell Lung Cancer – Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer's extent. Treatment options depend on the stage but may...
-
Product Insights
NewMycoses – Drugs In Development, 2024
Empower your strategies with our Mycoses – Drugs In Development, 2024 report and make more profitable business decisions. Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete's foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is...
-
Product Insights
NewLiver Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Liver Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or regrow. Liver transplantation replaces an injured or diseased liver with a healthy one; an entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it....
-
Product Insights
NewFanconi Anemia – Drugs In Development, 2024
Empower your strategies with our Fanconi Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Fanconi anemia, or FA, is a rare, inherited blood disorder that leads to bone marrow failure. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment...
-
Product Insights
NewPulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
NewNeuroendocrine Cancer – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Cancer – Drugs In Development, 2024 report and make more profitable business decisions. A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have...
-
Product Insights
NewIschemic Stroke – Drugs In Development, 2024
Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within...